Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
- Details
- Category: Novartis

Boehringer Ingelheim signs option to acquire Trutino Biosciences
- Details
- Category: Boehringer Ingelheim

Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases.
Positive Phase 1 data from mRNA-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer
- Details
- Category: Business

Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.
- Details
- Category: Pfizer

FDA approves RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for adults with moderate to severe rheumatoid arthritis
- Details
- Category: Amgen

Sandoz announces new global 'Act4Biosimilars' initiative
- Details
- Category: Novartis

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
- Details
- Category: GlaxoSmithKline

More Pharma News ...
- FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
- Roche develops unique PCR tests to detect the monkeypox virus
- Vaxzevria approved in the EU as third dose booster against COVID-19
- Pfizer 'aunches 'An Accord for a Healthier World' to improve health equity for 1.2 billion people living in 45 lower-income countries
- Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
- Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
- Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission